Literature DB >> 22909998

Predictive factors of positive circumferential resection margin after radiochemotherapy for rectal cancer: the French randomised trial ACCORD12/0405 PRODIGE 2.

Anne Rullier1, Sophie Gourgou-Bourgade, Marta Jarlier, Frédéric Bibeau, Catherine Chassagne-Clément, Christophe Hennequin, Laurent Tisseau, Agnès Leroux, Francette Ettore, Michel Peoc'h, Marie-Agnès Diebold, Yves-Marie Robin, Isabelle Kleinclaus, Laurent Mineur, Christophe Petitjean, Jean-François Mosnier, Isabelle Soubeyran, Norbert Padilla, Anne-Isabelle Lemaistre, Jocelyne Bérille, Bernard Denis, Thierry Conroy, Jean-Pierre Gérard.   

Abstract

Circumferential resection margin (CRM) appears as a new powerful prognostic factor of survival after surgery for rectal cancer. We aimed to evaluate predictive factors of positive CRM following preoperative radiochemotherapy in a French trial. Patients with rectal cancer were randomised in long course preoperative radiotherapy 45 Gy plus capecitabine versus 50 Gy plus capecitabine and oxaliplatin. Mesorectal excision was performed 6 weeks after treatment. Impact of clinical, pathological and surgical variables on positive CRM (≤1 mm) were analysed by multivariate analysis. Of 565 randomised patients, CRM was recorded in 390 cases and was positive in 8% (30/390). Patients with 50 Gy plus capecitabine and oxaliplatin had a 6% rate of positive CRM while those treated by 45 Gy plus capecitabine had a 10% rate (p=0.128). Three independent predictive factors of positive CRM were identified: abdominoperineal resection (APR) (odds ratio OR=3.24; p=0.004), vascular tumour invasion (OR=2.78; p=0.026) and poor histological response (modified Dworak 0-2) (OR=9.01; p=0.003). Significant predictive factors of positive CRM are related to type of surgery, especially APR, and poor histological prognostic factors. Intensification of neoadjuvant radiochemotherapy does not seem to have a major role in this study.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22909998     DOI: 10.1016/j.ejca.2012.06.028

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  21 in total

1.  Predicting the pathological features of the mesorectum before the laparoscopic approach to rectal cancer.

Authors:  Sonia Fernández Ananín; Eduardo M Targarona; Carmen Martinez; Juan Carlos Pernas; Diana Hernández; Ignasi Gich; Francesc J Sancho; Manuel Trias
Journal:  Surg Endosc       Date:  2014-06-21       Impact factor: 4.584

2.  Predictors of circumferential resection margin involvement in surgically resected rectal cancer: A retrospective review of 23,464 patients in the US National Cancer Database.

Authors:  Eisar Al-Sukhni; Kristopher Attwood; Emmanuel Gabriel; Steven J Nurkin
Journal:  Int J Surg       Date:  2016-02-21       Impact factor: 6.071

3.  Oncologic results and prognostic predictors of patients with locally advanced rectal cancer showing ypN0 after radical surgery following neoadjuvant chemoradiotherapy.

Authors:  Kyung-Ha Lee; Jae-Chan Kim; Ji-Yeon Kim; Jin-Su Kim
Journal:  Int J Colorectal Dis       Date:  2015-05-23       Impact factor: 2.571

Review 4.  Laparoscopic rectal cancer surgery: where do we stand?

Authors:  Mukta K Krane; Alessandro Fichera
Journal:  World J Gastroenterol       Date:  2012-12-14       Impact factor: 5.742

5.  High Rate of Positive Circumferential Resection Margins Following Rectal Cancer Surgery: A Call to Action.

Authors:  Aaron S Rickles; David W Dietz; George J Chang; Steven D Wexner; Mariana E Berho; Feza H Remzi; Frederick L Greene; James W Fleshman; Maher A Abbas; Walter Peters; Katia Noyes; John R T Monson; Fergal J Fleming
Journal:  Ann Surg       Date:  2015-12       Impact factor: 12.969

6.  Phase I trial of neoadjuvant preoperative chemotherapy with S-1, oxaliplatin, and bevacizumab plus radiation in patients with locally advanced rectal cancer.

Authors:  Hirohiko Sato; Mitsuo Shimada; Nobuhiro Kurita; Takashi Iwata; Kozo Yoshikawa; Jun Higashigima; Motoya Chikakio; Hideya Kashihara; Chie Takasu; Noriko Matsumoto; Shozo Eto
Journal:  Int J Clin Oncol       Date:  2014-08-01       Impact factor: 3.402

7.  Pre- and post-surgery treatments in rectal cancer: a long-term single-centre experience.

Authors:  H Ozyurt; A S Ozden; Z Ozgen; C Gemici; G Yaprak
Journal:  Curr Oncol       Date:  2017-02-27       Impact factor: 3.677

8.  HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.

Authors:  Jun Seok Park; Ghilsuk Yoon; Hye Jin Kim; Soo Yeun Park; Gyu Seog Choi; Min Kyu Kang; Jong Gwang Kim; Jung-Sik Jang; An Na Seo
Journal:  Virchows Arch       Date:  2018-07-28       Impact factor: 4.064

Review 9.  There is no difference in outcome between laparoscopic and open surgery for rectal cancer: a systematic review and meta-analysis on short- and long-term oncologic outcomes.

Authors:  M Pędziwiatr; P Małczak; M Mizera; J Witowski; G Torbicz; P Major; M Pisarska; M Wysocki; A Budzyński
Journal:  Tech Coloproctol       Date:  2017-08-09       Impact factor: 3.781

10.  Clinical influence of cancer stem cells on residual disease after preoperative chemoradiotherapy for rectal cancer.

Authors:  Ghilsuk Yoon; Sol-Min Kim; Hye Jin Kim; An Na Seo
Journal:  Tumour Biol       Date:  2015-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.